The report is available in English with a French summary - KCE

More documents

Recommendations

Info

96 Plasma KCE Reports 120 Table 41: Estimation of the proportion of immunoglobulins needed (or used) to treat 11 diseases in Belgium and in 4 studies Disease / medical condition IG amount in g per year (A) Idiopathic thrombocytopenic purpura (all) 32.850 - ITP in children (
KCE Reports 120 Plasma 97 3.3.4 Expected trends in consumption We have identified a few trends and scientific progresses that may influence future trends in IG use and consumption, to help predict future trends. 1. The number of allogenic bone marrow transplants performed in Belgium is increasing from year to year, from 216 in 2005 to 284 in 2007 (+31% in 2 years). In Europe, a study estimated a more conservative 13% rise in bone marrow transplants to be expected from 2005 to 2010. 194 This would imply an increased IG use over time. However, the increase in non-myeloablative transplants in adults, with a consequent lower level and shorter duration of hypogammaglobulinemia, would tend to decrease IG needs. 2. The prognosis of patients with MM has improved significantly during the last three decades, resulting in increased survival. 195 This will likely increase the disease prevalence and related needs in IG. But alternative therapies for MM and CLL are also increasingly used and this may result in decreased needs in IG supplementation. 3. The prevalence of multiple sclerosis and myasthenia gravis is increasing with time, due to ageing of the population and better diagnostic tools, and could result in increasing IG needs. 4. Alternative treatments for ITP and for the prevention of infections in transplant are under development. Some therapies are arriving on the market (e.g. Rituximab and Romiplostine) could potentially decrease IG use for these indications. 5. Many studies are conducted to test alternative treatment that would allow decreasing or even stopping IG maintenance treatment in CIDP cases. If successful and available, these therapies would decrease IG use for this disease. 6. Alzheimer disease, any auto-immune disease, asthma and some other frequent diseases related to immunity and for which no alternative treatment has shown efficacy, may be considered by some physicians as new indications for IG. This may represent a problem before any RCT could demonstrate the efficacy - or lack of efficacy - of IG for these diseases.
Page 1 and 2:
Comment assurer l’autosuffisance
Page 3 and 4:
Comment assurer l’autosuffisance
Page 5 and 6:
KCE Reports 120B Plasma i PRÉFACE
Page 7 and 8:
KCE Reports 120B Plasma iii MÉTHOD
Page 9 and 10:
KCE Reports 120B Plasma v En ce qui
Page 11 and 12:
KCE Reports 120B Plasma vii RECOMMA
Page 13 and 14:
KCE Reports 120 Plasma 1 Scientific
Page 15 and 16:
KCE Reports 120 Plasma 3 GLOSSARY A
Page 17 and 18:
KCE Reports 120 Plasma 5 1 INTRODUC
Page 19 and 20:
KCE Reports 120 Plasma 7 Focus: sta
Page 21 and 22:
KCE Reports 120 Plasma 9 Two techni
Page 23 and 24:
KCE Reports 120 Plasma 11 Therefore
Page 25 and 26:
KCE Reports 120 Plasma 13 FRENCH-SP
Page 27 and 28:
KCE Reports 120 Plasma 15 Number of
Page 29 and 30:
KCE Reports 120 Plasma 17 Table 4:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
KCE Reports 120 Plasma 23 Role of t
Page 37 and 38:
KCE Reports 120 Plasma 25 2.1.3.2 P
Page 39 and 40:
KCE Reports 120 Plasma 27 • 73% o
Page 41 and 42:
KCE Reports 120 Plasma 29 2.2 TRANS
Page 43 and 44:
KCE Reports 120 Plasma 31 Figure 6:
Page 45 and 46:
KCE Reports 120 Plasma 33 GEOGRAPHI
Page 47 and 48:
KCE Reports 120 Plasma 35 It is sur
Page 49 and 50:
KCE Reports 120 Plasma 37 Plasma fr
Page 51 and 52:
KCE Reports 120 Plasma 39 2.3 LIMIT
Page 53 and 54:
Page 55 and 56:
KCE Reports 120 Plasma 43 3.2 INDIC
Page 57 and 58: KCE Reports 120 Plasma 45 Subcutane
Page 59 and 60: KCE Reports 120 Plasma 47 Table 20:
Page 61 and 62: KCE Reports 120 Plasma 49 3.2.2 Evi
Page 63 and 64: KCE Reports 120 Plasma 51 Search re
Page 65 and 66: KCE Reports 120 Plasma 53 CIDP IG i
Page 67 and 68: KCE Reports 120 Plasma 55 • IG re
Page 69 and 70: KCE Reports 120 Plasma 57 Solid org
Page 71 and 72: KCE Reports 120 Plasma 59 A Cochran
Page 73 and 74: KCE Reports 120 Plasma 61 • In ch
Page 75 and 76: KCE Reports 120 Plasma 63 Two small
Page 77 and 78: KCE Reports 120 Plasma 65 was lower
Page 79 and 80: KCE Reports 120 Plasma 67 Three RCT
Page 81 and 82: KCE Reports 120 Plasma 69 Severe se
Page 83 and 84: KCE Reports 120 Plasma 71 The analy
Page 85 and 86: KCE Reports 120 Plasma 73 3.3.1.2 T
Page 87 and 88: KCE Reports 120 Plasma 75 Figure 7:
Page 89 and 90: KCE Reports 120 Plasma 77 Figure 10
Page 95 and 96: KCE Reports 120 Plasma 83 • For b
Page 97 and 98: KCE Reports 120 Plasma 85 3.3.2.6 L
Page 99 and 100: KCE Reports 120 Plasma 87 • The p
Page 101 and 102: KCE Reports 120 Plasma 89 In Belgiu
Page 103 and 104: KCE Reports 120 Plasma 91 Multifoca
Page 105 and 106: KCE Reports 120 Plasma 93 Based on
Page 107: KCE Reports 120 Plasma 95 Disease /
Page 111 and 112: KCE Reports 120 Plasma 99 Figure 12
Page 113 and 114: KCE Reports 120 Plasma 101 Key poin
Page 115 and 116: KCE Reports 120 Plasma 103 Key poin
Page 117 and 118: KCE Reports 120 Plasma 105 • Conf
Page 119 and 120: KCE Reports 120 Plasma 107 As far a
Page 121 and 122: KCE Reports 120 Plasma 109 Followin
Page 123 and 124: KCE Reports 120 Plasma 111 4.3 HOW
Page 125 and 126: KCE Reports 120 Plasma 113 Improvin
Page 127 and 128: KCE Reports 120 Plasma 115 4.3.2 St
Page 129 and 130: KCE Reports 120 Plasma 117 4.4 CONC
Page 131 and 132: KCE Reports 120 Plasma 119 FAVOURIN
Page 133 and 134: KCE Reports 120 Plasma 121 APPENDIX
Page 135 and 136: KCE Reports 120 Plasma 123 For othe
Page 137 and 138: KCE Reports 120 Plasma 125 Table 48
Page 143 and 144: KCE Reports 120 Plasma 131 Distribu
Page 145 and 146: KCE Reports 120 Plasma 133 • Conv
Page 149 and 150: KCE Reports 120 Plasma 137 6 REFERE
Page 151 and 152: KCE Reports 120 Plasma 139 41. Pruz
Page 153 and 154: KCE Reports 120 Plasma 141 82. Comi
Page 155 and 156: KCE Reports 120 Plasma 143 123. Cre
Page 157 and 158: KCE Reports 120 Plasma 145 165. Cua
Page 159 and 160:
This page is left intentionally bla
Page 161 and 162:
KCE reports 1. Efficacité et renta
Page 163 and 164:
73. Financement du programme de soi
show all

The report is available in English with a French summary - KCE

Create successful ePaper yourself

Delete template?

Save as template?